Issue Navigation
-
Review
-
258-272
Recent advances in Chinese patent medicines entering the international market
Zhang B, Pei WJ, Cai PP, Wang ZX, Qi FH
Drug Discov Ther. 2022; 16(6):258-272.
DOI: 10.5582/ddt.2022.01115
-
273-279
Screening for microbial potentiators of neutral lipid degradation in CHO-K1 cells
Nur EAA, Kobayashi K, Ohte S, Tomoda H, Ohshiro T
Drug Discov Ther. 2022; 16(6):273-279.
DOI: 10.5582/ddt.2022.01087
-
280-285
Hamamoto H, Miyashita A, Kamura K, Horie R, Sekimizu K
Drug Discov Ther. 2022; 16(6):280-285.
DOI: 10.5582/ddt.2022.01088
-
286-292
WRQ-2, a gemcitabine prodrug, reverses gemcitabine resistance caused by hENT1 inhibition
Wang RQ, Li YL, Gao JJ, Luan YP
Drug Discov Ther. 2022; 16(6):286-292.
DOI: 10.5582/ddt.2022.01077
-
293-296
Membrane translocation of vinculin after UVA exposure facilitates melanosome trafficking
Yamamoto H, Tanaka C, Okada M, Sawaguchi Y, Yamada T
Drug Discov Ther. 2022; 16(6):293-296.
DOI: 10.5582/ddt.2022.01075
-
297-299
Valemetostat: First approval as a dual inhibitor of EZH1/2 to treat adult T-cell leukemia/lymphoma
Dou FZ, Tian ZX, Yang X, Li J, Wang RQ, Gao JJ
Drug Discov Ther. 2022; 16(6):297-299.
DOI: 10.5582/ddt.2022.01085
-
300-304
Molecular and immunological diagnosis of Monkeypox virus in the clinical laboratory
Liao H, Qu JX, Lu HZ
Drug Discov Ther. 2022; 16(6):300-304.
DOI: 10.5582/ddt.2022.01093
-
305-308
Wang C, Sun LQ, Li Q, Lu HZ
Drug Discov Ther. 2022; 16(6):305-308.
DOI: 10.5582/ddt.2022.01082
-
309-312
Iwata H, Nakamura K, Kobayashi N, Fujimoto K, Hayashi N, Yamaura K
Drug Discov Ther. 2022; 16(6):309-312.
DOI: 10.5582/ddt.2022.01091
-
313-315
Zhong YS, Cai MH, Zhong ZM, Zhang Y, Deng MH, Lin N
Drug Discov Ther. 2022; 16(6):313-315.
DOI: 10.5582/ddt.2022.01078
-
316-317
Relaxation of all-case reporting of COVID-19 cases in Japan
Karako K
Drug Discov Ther. 2022; 16(6):316-317.
DOI: 10.5582/ddt.2022.01073